Chondrosarcoma is a type of bone cancer that begins in the cartilage (firm connective tissue that covers the ends of bones) or in other parts of the body made of cartilage. Common symptoms of chondrosarcoma include bone pain, swelling near the affected area and limited range of motion. Treatment options for chondrosarcoma include surgery to remove the tumor, chemotherapy and radiation therapy. Advancements in diagnosis and treatment modalities are driving growth of the chondrosarcoma market.
The chondrosarcoma market is estimated to be valued at USD 961.2 Mn in 2024 and is expected to reach USD 1,521.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
Key Takeaways
Key players operating in the chondrosarcoma market are Pfizer, Eli Lilly, Johnson & Johnson, Bayer AG, Bristol-Myers Squibb Company, Ipsen Pharma, Hoffmann-La Roche Ltd., Merck & Co., Inc.
Rising incidence of cancer globally is fueling demand for chondrosarcoma treatment. According to WHO, cancer burden has risen to 18.1 million new cases and 9.6 million deaths in 2018. Improving healthcare infrastructure and spending in emerging nations is also boosting the Chondrosarcoma Market.
Major players are expanding their presence globally to tap the growth opportunities. For instance, in 2020, Johnson & Johnson entered into a licensing agreement with CENTOGENE for rare bone tumor biomarkers to aid diagnosis of chondrosarcoma.
Market key trends
Combination therapy is emerging as a major trend in chondrosarcoma treatment. Combining conventional therapies like chemotherapy and radiation with targeted therapies can enhance efficacy and reduce adverse effects. Biotechs are involved in developing targeted therapies against molecular pathways driving chondrosarcoma. For example, phase 2 trials are ongoing to evaluate MEK inhibitors in combination with chemotherapy for chondrosarcoma.
Porter's Analysis
Threat of new entrants: The large capital requirements and economies of scale in production and marketing pose barriers to entry in this market.
Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of alternative treatment options for chondrosarcoma.
Bargaining power of suppliers: A few major players dominate the supply side, giving them significant influence over prices in the market.
Threat of new substitutes: Ongoing research into alternative treatment methods can lead to new product substitutes entering the market.
Competitive rivalry: Companies compete based on product differentiation, pricing, and marketing capabilities.
Geographical Regions
North America currently holds the largest share of the global chondrosarcoma market, supported by advanced healthcare infrastructure and high treatment rates in the region.
Asia Pacific is poised to witness the fastest growth during the forecast period, due to growing healthcare awareness, rising disposable incomes, and improvements in medical technologies across developing economies in the region.
Get this Report in Japanese Language: 軟骨肉腫市場
Get this Report in Korean Language: 연골육종 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
